Enfermedad cardiovascular previa y posterior a la infección por COVID-19. Supervivencia a un año / Cardiovascular disease before and after COVID-19 infection: One-year survival

Objetivos Analizar el riesgo de COVID-19 con relación a la morbilidad previa, así como el riesgo de nuevos eventos cardiovasculares (ECV) en pacientes COVID-19 y la supervivencia a un año. Metodología Estudio casos-control y estudio de cohortes prospectivo. Se incluyeron 275 pacientes aleatorizados >18 años diagnosticados de COVID-19 y se aparearon con 825 COVID-19 negativos por edad y sexo (proporción 1:3). Las variables principales fueron diagnóstico de COVID-19 y eventos post-COVID-19. Se estudiaron variables sociodemográficas, comorbilidad y ECV previo. Se realizaron sendos modelos predictivos de factores asociados al desarrollo de COVID-19 y de ECV post-COVID-19, así como un análisis de supervivencia a un año. Resultados Los varones con ECV previo duplican el riesgo de padecer COVID-19 (odds ratio [OR] 2,11; intervalo de confianza [IC] 95% 1,32–3,36). En las mujeres el riesgo aumenta con la edad (OR 1,01; IC 95% 1,00–1,02), la diabetes mellitus (DM) (OR 1,90; IC 95% 1,14–3,17) y el deterioro cognitivo (OR 4,88; IC 95% 2,50–9,53). La inmunosupresión actúa como factor protector en ambos sexos. La edad (OR 1,02; IC 95% 1,00–1,04), hipertensión arterial (HTA) (OR 2,21; IC 95% 1,17–4,17), la infección COVID-19 (OR 4,81; IC 95% 2,89–7,98) y el ECV previo (OR 4,46; IC 95% 2,56–7,75) predicen el desarrollo de un nuevo ECV post-COVID-19. Los pacientes COVID-19 positivos tienen menor supervivencia (mediana de siete vs. 184 días). Conclusiones El ECV previo en varones y la DM junto al deterioro cognitivo en mujeres aumentan el riesgo de presentar COVID-19. La edad, HTA, ECV previo y la infección COVID-19 predicen la aparición de un ECV (AU)

Aim To analyze the risk of COVID-19 in relation to previous morbidity; to analyze the risk of new cardiovascular events (CVE) in COVID-19 patients and one-year survival. Methodology Case–control study and prospective cohort study. Two hundred and seventy-five randomized patients >18 years old with COVID-19 were included and matched with 825 without COVID-19 by age and sex (ratio 1:3). The main variables were diagnosis of COVID-19 and post-COVID-19 events. Sociodemographic variables, comorbidity, and previous CVD were studied. Two predictive models of factors associated with the development of COVID-19 and post-COVID-19 CVE were performed, as well as a one-year survival analysis. Results Men with a previous CVE double the risk of suffering from COVID-19 (OR 2.11; 95% CI: 1.32–3.36). In women, the risk increases with age (OR 1.01; 95% CI: 1.00–1.02), diabetes (DM) (OR 1.90; 95% CI: 1.14–3.17) and cognitive impairment (OR 4.88; 95% CI: 2.50–9.53). Immunosuppression acts as a protective factor in both sexes. Age (OR 1.02; 95% CI: 1.00–1.04), arterial hypertension (OR 2.21; 95% CI: 1.17–4.17), COVID-19 infection (OR 4.81; 95% CI: 2.89–7.98) and previous CVE (OR 4.46; 95% CI: 2.56–7.75) predict the development of a new post-COVID-19 CVE. Positive COVID-19 has lower survival (median 7 days vs. 184 days). Conclusions Previous CVE in men and DM along with cognitive impairment in women increase the risk of presenting COVID-19. Age, arterial hypertension, previous CVE, and COVID-19 infection predict the appearance of new CVE (AU)

[Cardiovascular disease before and after COVID-19 infection: One-year survival]. / Enfermedad cardiovascular previa y posterior a la infección por COVID-19. Supervivencia a un año.

AIM: To analyze the risk of COVID-19 in relation to previous morbidity; to analyze the risk of new cardiovascular events (CVE) in COVID-19 patients and one-year survival. METHODOLOGY: Case-control study and prospective cohort study. Two hundred and seventy-five randomized patients >18 years old with COVID-19 were included and matched with 825 without COVID-19 by age and sex (ratio 1:3). The main variables were diagnosis of COVID-19 and post-COVID-19 events. Sociodemographic variables, comorbidity, and previous CVD were studied. Two predictive models of factors associated with the development of COVID-19 and post-COVID-19 CVE were performed, as well as a one-year survival analysis. RESULTS: Men with a previous CVE double the risk of suffering from COVID-19 (OR 2.11; 95% CI: 1.32-3.36). In women, the risk increases with age (OR 1.01; 95% CI: 1.00-1.02), diabetes (DM) (OR 1.90; 95% CI: 1.14-3.17) and cognitive impairment (OR 4.88; 95% CI: 2.50-9.53). Immunosuppression acts as a protective factor in both sexes. Age (OR 1.02; 95% CI: 1.00-1.04), arterial hypertension (OR 2.21; 95% CI: 1.17-4.17), COVID-19 infection (OR 4.81; 95% CI: 2.89-7.98) and previous CVE (OR 4.46; 95% CI: 2.56-7.75) predict the development of a new post-COVID-19 CVE. Positive COVID-19 has lower survival (median 7 days vs. 184 days). CONCLUSIONS: Previous CVE in men and DM along with cognitive impairment in women increase the risk of presenting COVID-19. Age, arterial hypertension, previous CVE, and COVID-19 infection predict the appearance of new CVE.

[Ability to predict hospitalization and resource requirements: comparison of the 3M Triage Assistance system and the combined Spanish Triage System and Andorran Triage Model]. / Comparación de la capacidad de predecir hospitalización y consumo de recursos del Programa de Ayuda al Triaje 3M TAS y el Sistema Español de Triaje ­ Model Andorrà de Triaje (SET-MAT).

OBJECTIVES: To determine the validity of 2 triage systems: the 3M Triage Assistance System (3M-TAS) and the combined Spanish Triage System and Andorran Triage Model (SET-MAT) for predicting hospitalization and use of emergency resources; and to estimate the level of agreement between them. MATERIAL AND METHODS: Prospective observational study of consecutive cohorts classified with the studied triage systems in the emergency department (ED) of a secondary-level hospital between March 24 and April 30, 2014. Patients were classified blindly and simultaneously between 9 AM and 10 PM by a clinical nurse using the SET-MAT program and a researcher nurse using the 3M-TAS software. We collected patients' demographic details and assigned triage level, laboratory and imaging tests ordered, specialist consultations requested in the ED, length of stay until discharge from the department, and destination on discharge. Outcome variables were hospitalization and use of at least 1 resource in the ED. RESULTS: A total of 3379 emergencies were included. The conventionally weighted κ statistic for agreement between the 2 triage systems was 0.26, but the triage-weighted κ was 0.17. The 3M-TAS software was better able to predict hospitalization than the SET-MAT (P<.001); however, the 2 systems, predictions of resource usage were similar (P=.111). CONCLUSION: Agreement between the 3M-TAS and SET-MAT triage systems was poor, although they predicted similar use of resources in the ED. The 3M-TAS was better able to predict hospital admission than the SET-MAT.

OBJETIVO: Determinar el grado de concordancia y validez, a la hora de predecir la hospitalización y el consumo de recursos en urgencias, del Sistema de Ayuda al Triaje 3M TAS y su comparación con el Sistema Español de Triaje - Model Andorrà de Triatge (SET-MAT). METODO: Estudio observacional de cohortes prospectivo que incluyó de forma consecutiva los episodios filiados de 9 a 22 horas en un servicio de urgencias de un hospital secundario entre el 24 de marzo y el 30 de abril de 2014. Los pacientes se clasificaron de forma enmascarada y simultánea por una enfermera asistencial mediante el programa de ayuda al triaje SET-MAT y por una enfermera de investigación mediante el 3M TAS. Se recogieron variables demográficas, de gravedad, las pruebas de laboratorio, radiológicas e interconsulta a especialistas realizadas en urgencias, el tiempo de estancia y el destino final. Las variables de resultado fueron la hospitalización y el consumo de al menos un recurso en urgencias. RESULTADOS: Se incluyeron 3.379 episodios. El índice de concordancia mediante el kappa ponderado cuadrático entre los sistemas de triaje fue de 0,26 y el kappa triaje de 0,17. El sistema 3M TAS presentó una mayor capacidad predictiva de hospitalización en comparación con el SET-MAT (p < 0,001), no siendo así en lo que respecta al consumo de recursos en urgencias (p = 0,111). CONCLUSIONES: La concordancia entre los sistemas de triaje 3M TAS y SET-MAT fue baja, sin diferencias para predecir el consumo de recursos en urgencias, aunque el 3M TAS predijo mejor ingreso hospitalario que el SET-MAT.

The value of a formula including haematocrit, blood urea and gender (HUGE) as a screening test for chronic renal insufficiency.

INTRODUCTION: Despite increasing use in clinical practice, an estimated glomerular filtration rate value (eGFR) of <60 ml/min/1.73 m2 does not necessarily indicate the existence of chronic renal insufficiency (CRI) and this may lead to an over-estimate of CRI particularly in persons seventy years or older. AIM: To find a screening test able to differentiate CRI from the decrease in GFR normally associated with the renal ageing process. METHODS: Medical information of 487 individuals of both sexes aged 16-102 was obtained from nephrologists, internal medicine physicians, cardiologists, geriatricians, family and nuclear medicine doctors from Argentina, Portugal and Spain. Data were assessed and statistically analysed using logistic regression techniques. From the discriminative variables it was derived the HUGE formula. RESULTS: A formula including haematocrit , blood urea, and gender (HUGE), diagnoses CRI regardless of the variables of age, blood creatinine, creatinine clearance, or other eGFR. The HUGE formula is: L = 2.505458 - (0.264418 x Hematocrit) + (0.118100 x Urea) [+ 1.383960 if male]. If L is a negative number the individual does not have CRI; if L is a positive number, CRI is present. Our data demonstrate that the HUGE formula is more reliable than MDRD and CKD-EPI, particularly in persons aged over 70. CONCLUSIONS: Our HUGE screening formula offers a straightforward, easily available and inexpensive method for differentiating between CRI and eGFR < 60 ml/min/1.73 m2 that will prevent a considerable number of aged healthy persons, as much as 1.700.000 in Spain and 2.600.000 in U.K., to be excluded from clinical assays or treatments contraindicated in CRI.